Mon panier

CD133

CD133 Informations sur la molécule

Nom anglaisCD133Nombre de médicaments commercialisés0
Nombre de médicaments cliniques2Alias de la cibleAntigen AC133,Prominin-1,PROM1,Prominin 1,Prominin-Like Protein 1,PROML1,Stargardt Disease 4 (Autosomal Dominant),Hematopoietic Stem Cell Antigen,Macular Dystrophy, Retinal 2,Prominin (Mouse)-Like 1,CD133 Antigen,HProminin,MSTP061,CORD12,AC133,CD133,MCDR2,STGD4,RP41,AC133 Antigen
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisCD133
Alias de la cibleAntigen AC133,Prominin-1,PROM1,Prominin 1,Prominin-Like Protein 1,PROML1,Stargardt Disease 4 (Autosomal Dominant),Hematopoietic Stem Cell Antigen,Macular Dystrophy, Retinal 2,Prominin (Mouse)-Like 1,CD133 Antigen,HProminin,MSTP061,CORD12,AC133,CD133,MCDR2,STGD4,RP41,AC133 Antigen
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques2
Phase de R&D la plus avancéePhase 2 Clinical

CD133 Liste de produits

  • Attribut

    Protein (7)Cell (1)

  • Bibliothèque de produits

    En ligne (8)

  • Espèces

    Human (7)Cynomolgus (1)

  • Étiquette

    His Tag (3)- (3)His Tag & Avi Tag (1)His Tag & Flag Tag (1)

  • Marqueur

    Unconjugated (4)Biotin-labeled (2)- (1)PE Labeled (1)

CD133Contexte de la molécule

Prominin-1 is also known as CD133, Antigen AC133, PROM1, PROML1 and MSTP061. Is used as marker for hematopoietic stem and progenitor cells (HSPC) for somatic stem cell isolation. May play a role in cell differentiation, proliferation and apoptosis . Binds cholesterol in cholesterol-containing plasma membrane microdomains and may play a role in the organization of the apical plasma membrane in epithelial cells. During early retinal development acts as a key regulator of disk morphogenesis. Involved in regulation of MAPK and Akt signaling pathways. In neuroblastoma cells suppresses cell differentiation such as neurite outgrowth in a RET-dependent manner.

CD133Alias de la molécule

CD133,PROM1,PROML1,Prominin-1,AC133

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
P-134P-134; P134Phase 2 ClinicalTianjin Tasly Pharmaceutical Co LtdGlioblastoma
Details
anti-CD133-CAR vector-transduced T cellsPhase 2 ClinicalPla General HospitalBrain Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques